Since the model of TIDE was developed and validated based on melanoma patients treated with first-line anti-PD1 or anti-CTLA4, TMEscore can be used as a biomarker to predict the tumor response to anti-PD1 or anti-CTLA4, but whether TMEscore can predict the tumor response to other ICIs remains uncertain. This evidence concerns the gene CTLA4 and neoplasm.